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Abstract 
In Finland, between 2003 and 2010 and parallel to the increase in
the prevalence of insomnia-related symptoms among the general pop-
ulation, there has been a cessation of growth and even a decrease in
the consumption of traditional hypnotics. The reasons behind this
seemingly paradoxical situation are not known. We analyzed trends
over the period 2000-2010 in the estimated consumption of traditional
hypnotics and some new drugs that are destined for use in insomnia
treatment. We used the annual wholesale statistical database compiled
by the Finnish Medicine Agency, FIMEA, and data from the Finnish
Drug Prescription Register. We found evidence to support two parallel
trends in Finnish outpatient care. First, there seems to be a trend in
which physicians increasingly comply with official guidelines for
insomnia treatment, which partly accounts for the decrease in the con-
sumption of traditional hypnotics. Second, at the same time, the first
trend seems to be resulting in an increasing trend to treat insomnia
patients with some new drugs that were not originally developed for
insomnia treatment by prescribing these non-hypnotic drugs in small,
sub-clinical doses. The current trend in practice may have contradicto-
ry effects on the treatment of insomnia. The long-term consequences
of using low doses of drugs other than hypnotics to treat insomnia are
not known and the situation should, therefore, be followed-up in sub-
sequent studies. However, pharmacological treatment should never be
a substitute for non-pharmacological treatments of insomnia.
Introduction
In Finland, between the years 1972 and 2005, occasional insomnia-
related symptoms have increased, especially among the employed and
working age population.1 The same study also found evidence of a pos-
sible smaller increase in chronic insomnia-related symptoms over the
past ten years. In addition, our unpublished results indicate a contin-
ued increase in the same symptoms in the years after 2005 (E.
Kronholm, unpublished results, 2009). The potential health implica-
tions of these trends may be important. Recent studies have found that
Insomnia-related symptoms predict future morbidity and mortality,2-5
as well as disability retirement.6-10 In addition, insomnia and insom-
nia-related symptoms precede depression and insomnia may be a risk
factor for this; but the association may also be bi-directional.11-17
In clinical practice, the long-term treatment of insomnia is often
largely based on sleep medication, in spite of guidelines to the con-
trary.18,19 Although short-term hypnotic treatment has been demon-
strated to be effective, a substantial proportion of patients have proven
to be resistant to the treatment or do not gain much benefit.19 In addi-
tion, there is increasing evidence to suggest that the use of sleep med-
icine has been associated with serious health risks.20-22 Therefore, the
question regarding the long-term pharmacological treatment of chron-
ic insomnia, at least in Europe, is unresolved and urgently needs to be
answered.23
In Finland, in parallel with the increase in the prevalence of insom-
nia-related symptoms among the general population, there has been a
significant increase in the consumption of hypnotics (ATC code
N05C). Between the years 1975 and 2005, the consumption of hyp-
notics has increased 2.8-fold.1 However, beginning in the year 2004,
there has been a halt in the increase in the consumption of hypnotics
and this has even started to decline. The reasons behind this decrease
are unclear. One possibility is that physicians in clinical practice have
begun to demonstrate greater compliance with the instructions given
by the official guidelines for insomnia treatment. However, there is
also another possible explanation.
Recent years have seen an ongoing discussion among Finnish sleep
specialists. This could be the result of an increasing condemnation of
the long-term use of hypnotic medication and, for this and other such
reasons, increasing numbers of clinical practitioners in Finland may
have begun prescribing antidepressants and other drugs instead of
hypnotics to treat insomnia. When used to treat insomnia, the doses
for these drugs are, in general, much lower than the official indication
for a given drug. We decided to explore the trends in the sale of tradi-
tional hypnotics (ATC code N05C) and in the sub-clinical doses for
antidepressives (N06A), as well as antipsychotics (N05A) and an
antiepileptic drug (pregabalin) during the time period when the
Significance for public health
Insomnia and sleeplessness are increasingly recognized as a public health
concern in contemporary Western societies. The official guidelines for
insomnia treatment in Finland have been constantly striving for a decline in
the use of sleep medication for long-term insomnia treatment. During recent
years there has been a gradual decrease in the annual consumption of sleep
medication. Thus, one would think that the measures endorsed by the guide-
lines have been successful. However, the situation is more complicated. The
decrease in traditional hypnotic use may be partly misleading. There seems
to be a current and continuing trend in outpatient care to increasingly
replace traditional hypnotics with subclinical doses of some other drugs not
originally developed for insomnia treatment, including antidepressives,
antipsychotics and antiepileptics. The long-term consequences of this prac-
tice are unknown and therefore a potential public health concern.
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increase in the consumption of traditional hypnotics had stopped and
even begun to decline, but when a parallel increase in the prevalence
of insomnia-related symptoms among the general population has also
taken place.1 We hypothesized that the use of medication for insomnia
has, in reality, not decreased, but that the increase in the use of tradi-
tional hypnotics has been replaced by sub-clinical doses of antidepres-
sants and other drugs.
Design and MethodsData sources 
We used an annual wholesale statistical database compiled by the
Finnish Medicine Agency, FIMEA.24 The figures in the database repre-
sent the volume of sales to pharmacies and hospitals by the two largest
drug wholesalers in Finland, which together account for nearly 100% of
total national drug sales. The remaining sales (approximately 1%) are
mainly hospital sales. The statistics include preparations registered for
human use in outpatient care and in institutions. 
The database lists drugs according to the World Health
Organization’s Anatomical Therapeutic Chemical (ATC) Classification
System25 and calculates the consumption of such drugs using the
assumed average maintenance dose per day for each drug according to
its main indication for adults. The consumption is expressed as
Defined Daily Dose (DDD) per 1000 inhabitants per day. At the end of
2010, the Finnish population was 5.38 million. Analysis of drug consumption
Using the above-mentioned data source, we analyzed trends during
2000-2010 in the consumption of traditional hypnotics (N05C), antide-
pressives (N06A), an antiepileptic drug (pregabalin, N03AX16), and
antipsychotics quetiapine (N05AH04) and levomepromazine
(N05AA02) by different tablet strengths. We chose the drugs based on
clinical experience and published recommendations.26 That is, we
included in our study the drugs generally believed to be widely used to
promote sleep in Finland. Several national recommendations have
been published on the treatment of insomnia,27 but it is still unknown
whether or not clinical practice is in line with these guidelines. 
We reasoned that if a drug with tablets of several strengths and a
main indicator other than insomnia was consumed in a low tablet
strength (that is used with a daily dosage well below the recommended
therapeutic maintenance dosage range for its main indication), it was
considered to be most likely used for the treatment of insomnia. The
reasoning for using these particular tablet strengths and drug doses
was also based on clinical experience and general information on the
doses commonly used by clinicians in everyday practice for treating
insomnia. Table 1 shows drugs destined for use in promoting sleep in
place of traditional hypnotics, the strength of the tablets for sale, the
typical number of doses in the main indication, and when they are sup-
posed to be taken as a hypnotic.
The annual number of individuals who purchased N05C drugs was
derived from the Finnish Drug Prescription Register. All drugs pre-
scribed by physicians to outpatients and reimbursed by the national
Health Insurance Scheme are included in the Finnish Drug
Prescription Register, which was established in 1993 and is maintained
by the Social Insurance Institution of Finland.30
Results
Figure 1 shows trends in the annual total consumption of tradition-
al hypnotics (N05C) from 1990 to 2010. The combined consumption of
traditional hypnotics in outpatient and institutional care increased
almost every year between 1990 and 2003 (from 35.1 to 55.9 DDD/1000
inhabitants/day, respectively). After 2003, the consumption of these
drugs began to decline: by 2010, the level of consumption was 49.1
DDD/1000 inhabitants/day. The total decrease was 6.8 DDD/1000 inhab-
itants/day (12.2%). When we analyzed the annual consumption for out-
patient care only, the number decreased from 50.8 to 47.0 DDD/1000
inhabitants/day between 2003 and 2010. Thus, the total decrease was
3.8 DDD/1000 inhabitants/day (7.5%). Consequently, the total decrease
in institutional care was 3.0 DDD/1000 inhabitants/day (58.8%). 
In outpatient care, increasing trends in the annual consumption of
the drugs under study according to different tablet strengths were
observed (Figure 2). We found the most striking increase in the con-
sumption of the antidepressant mirtazapine (tablet strength 15 mg).
Between 2002 and 2010, the level of consumption of this drug increased
from 0.03 to 2.4 DDD/1000 inhabitants/day. It accounted for 61% of the
total increase in the use of this drug. We found the next highest
increase in the consumption of the antidepressant amitriptyline (10
mg and 25 mg). Between 2000 and 2010, the level of consumption of
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Table 1. Some drugs that are destined for use in Finland (2000-2010) to promote sleep instead of traditional hypnotics (N05C). 
Generic name ATC code Strength of tablets (mg) Strength of therapeutic dose (mg/d) Strength of dose (mg/d)
of drug in Finland for main indication for insomnia treatment
Amitriptyline N06AA09 10; 25; 50 50-75 (pain)24 10-25 (max 50)24
150-300 (depression)24
Doxepin N06AA12 10; 25; 50 75-150 (ad 300)24 1-10; 10-25 (max 50)24
Mianserin N06AX03 10; 30; 60 60-90 (ad 120)24 10-30
Trazodone N06AX05 50; 100 150-300 (ad 600)24 25-10024
Mirtazapine N06AX11 15; 30; 45 15-45  3.75-7.5 (15)27
Levomepromazine N05AA02 5; 25; 50; 100 ad 75024 5-10024
Quetiapine N05AH04 25; 50; 100; 200; 300; 400 300-450 (schizophrenia)24 25-10028
200-800 (bipolar affective disorder)24
Pregabalin N03AX16 25; 75; 150; 225; 300 150-600 (epilepsy, neuropathic pain, and 25-50°
generalized anxiety disorder)29










this drug increased from 1.33 to 1.95 DDD/1000 inhabitants/day.
Notably, these figures accounted for 87% of the total increase in the use
of amitriptylin; the use of 50 mg tablets accounted for only a 13%
increase in the level of consumption. Consumption of the antipsychot-
ic drug quetiapine (25 mg) increased from 0.02 to 0.53 DDD/1000
inhabitants/day. The increase in the use of small doses (25 mg, 50 mg,
and 100 mg) of quetiapine accounted for 38% of the total increase in
the use of this drug. Notably, use of a new antiepileptic drug called pre-
gabalin (25 mg) increased from 0.02 to 0.21 DDD/1000 inhabitants/day
between the years 2003 and 2010. This represents a remarkable 10-fold
increase in the level of consumption of the sub-clinical strength of the
drug within eight years. Other non-hypnotics considered to have been
used for insomnia treatment showed either a decreasing trend in the
annual level of consumption of sub-clinical doses (mianserin 30 mg
and doxepin 25 mg) or virtually no meaningful trend at all (levomepro-
mazine 5 mg and 25 mg, and mianserin 10 mg) (Figure 3). Trazodone,
which can be used for insomnia treatment also in its strongest tablet
strength, did not show any meaningful trend in its consumption (0.14
DDD/1000 inhabitants/day in 2001 and 0.15 in 2010) and was, there-
fore, left out of further analyses and figures.
The decrease in the annual consumption of traditional hypnotics
during the period 2003-2010 in outpatient care was 3.8 DDD/1000
inhabitants/day (Figure 1). At the same time, the total increase in the
annual consumption of drugs other than ATC group N05C hypnotics,
which are destined for use in the treatment of insomnia, was 3.2
DDD/1000 inhabitants/day, accounting for 84% of the total decrease in
the consumption of traditional hypnotics. 
Data from the Finnish Drug Prescription Register (Table 2) showed
that the number of individuals who received reimbursement for N05C
drugs increased between 2006 and 2009 by 61,540 individuals.
Consequently, it can be inferred that the number of used doses per
patient may have decreased during those four years. However, their
number first started to decline in 2010 when a total of 356,192 outpa-
tients requested reimbursement for at least one prescription of N05C
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Figure 1. Trends in annual consumption of traditional hypnotics
(ATC group N05C) (1990-2010).
Figure 2. Increase in trends of annual consumption of sub-clini-
cal doses of some antidepressants and other drugs supposedly
used instead of hypnotics to treat insomnia in outpatient care.
Figure 3. The decrease or absence of any trend in sub-clinical










[page 152] [Journal of Public Health Research 2012; 1:e23]
drugs, resulting in a decrease of 3.7%. The register covered 86% of the
total consumption of N05C drugs (assessed by wholesale DDDs) in
Finnish outpatient care. The data from 2011 show a further decline
(347,873 individuals in 2011, a decrease of 8319 individuals) when
compared to 2010.
Discussion
The main finding of this study was that the apparent decrease in the
annual use of sleep medication based on statistics for ATC group N05C
hypnotics may be partially misleading. The consumption of traditional
hypnotics has dramatically decreased in institutional care, but in outpa-
tient care the decrease has most likely been caused by a shift in the pre-
scribing practices of physicians in Finland. It is quite likely that, during
the last few years, an increasing number of practitioners have replaced
ATC group N05C hypnotics with sub-clinical doses of some ATC group
N06A antidepressants (i.e. mirtazapine and amitriptyline) and some
other drugs (i.e. the antipsychotic drug quetiapine and the antiepileptic
drug pregabalin). This change in the treatment of insomnia seems to be
continuing. It seems that the effort to decrease the use of sleeping med-
icine within the health care system27 has not been as successful as one
might have thought. There is a general lack of therapists in the Finnish
health care system and most resources are channelled to the treatment
of major psychiatric conditions. Only a few psychologists or physicians
are trained to treat insomnia with Cognitive-Behavioral Therapy for
insomnia (CBTi). Furthermore, to our knowledge and to the knowledge
of the sleep specialists in Finland (J. Markkula, personal communication,
2012), there has been no major increase either in the use or training of
CBTi in Finland during the past decades. Thus, the decrease in the use
of hypnotics has not resulted in an increase in the use of cognitive and
behavioral treatments for insomnia within the Finnish health care sys-
tem. Rather, it has merely resulted in an apparent shift from one class of
drugs to another. We were able to account for 84% of the total decline in
the consumption of traditional hypnotics via a transition to the use of
sub-clinical doses of mirtazapine, amitriptyline, quetiapine and prega-
balin in outpatient care. There are some other drugs which are also prob-
ably used instead of the traditional hypnotics, but the purpose for which
these drugs are used cannot be inferred from the tablet strength.
Consequently, we may have slightly underestimated the full extent of the
transition in drug use. However, the number of individuals who received
reimbursements for traditional hypnotics has also increased by 20%
between 2006 and 2009. Given that the total sales in outpatient care have
decreased during the same period, this suggests that the number of
doses of traditional hypnotics per patient has decreased and/or the dura-
tion of treatment has been shortened. In turn, this would suggest that
physicians are increasingly demonstrating greater compliance with the
guidelines for insomnia treatment. This increasing compliance to offi-
cial guidelines by physicians may decrease the consumption of N05C
drugs partly also by increased prescriptions for intermittent (non-night-
ly) use of traditional hypnotics, which has been suggested, although not
generally accepted among clinicians, to be a possible strategy to prevent
intolerance and maintain efficacy. This could explain part of the decrease
in the consumption although the number of patients had increased.
However, this possible trend could hardly account for the total decrease
in N05C consumption. First, from Table 2 it can be calculated that the
ratio of consumption of reimbursed DDD/year to the number of persons
receiving reimbursement for N05C drugs has shown only a small
decrease between 2006 and 2010, suggesting that the clinical practices
among patients continuing to use N05C drugs remain relatively con-
stant. Second, notably during the last two years there has been a
decrease in the number of persons who have received reimbursement for
N05C drugs at the same time as the consumption of sub-clinical doses of
antidepressants and some other new drugs has increased. Given that the
prevalence of insomnia-related symptoms has increased, it seems
unlikely that the decrease in reimbursement figures of N05C drugs
would reflect the increased prevalence of non-pharmacological treat-
ment. On the contrary, availability of CBTi in Finland remains scarse. We
are, therefore, inclined to conclude that there seem to be two parallel,
probably interrelated, processes behind the decrease in the consumption
of traditional hypnotics in outpatient care during the last seven years in
Finland: physicians increasingly complying with the official guidelines
for insomnia treatment and a shift from traditional hypnotics to other
drugs not originally developed for insomnia treatment. Taken together,
these trends suggest that a continuously increasing number of insomnia
patients are treated with different drugs and that only a small part of the
decrease in the use of traditional hypnotics can be explained by
increased compliance with the official guideline instructions for insom-
nia treatment, which promote the use of non-pharmacological treat-
ments for chronic insomnia.  For the most part, the decrease in the use
of traditional hypnotics seems to be explained by a shift to other types of
drugs. Importantly, in addition to the possible health risks supposedly
associated with the use of N05C group hypnotics,22,31,32 the long-term
consequences of the use of new antidepressants and epileptic and
antipsychotic drugs in sub-clinical doses as insomnia treatment are
known to also pose a risk.26
The strength of our study is that we had annual wholesale data from
the outpatient care system at our disposal, including information on pre-
scription and over-the-counter drugs, as well as reimbursed and non-
reimbursed drugs or packages of the same drug. However, it should be
noted that all target drugs in this study are available by prescription only,
according to Finnish legislation. There are also limitations in our study
which should be considered when interpreting the results. First, the
study was based on public statistics, so we did not have access to patient-
level data. Second, although the use of wholesale data can be considered
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Table 2. Total consumption of hypnotics (in Defined Daily Doses, DDDs), as assessed according to the wholesale data and the Drug
Prescription Register for N05C drugs used in outpatient care during 2005-2010. 
Year Total consumption Reimbursed consumption Coverage % of reimbursed N. of persons
of N05C drugs of N05C drugs consumption of N05C drugs receiving reimbursement
DDD (million) DDD (million) from total consumption for N05C drugs
2005 96.9 66.7 68.9 252.684
2006° 96.5 73.9 76.5 308.331
2007 97.8 77.4 79.2 334.180
2008 97.4 77.6 79.7 342.073
2009 93.0 79.5 85.5 369.871
2010 87.5 75.4 86.2 356.192
°At the beginning of 2006, the method of calculating reimbursement payments in the Finnish insurance system changed. With the reform, the fixed non-reimbursable sum paid by the patient per purchase (≤10
euros) was abandoned. In the new system, the reimbursement payment is calculated separately for each medical product and almost every purchase of N05C drugs (with approved reimbursement status) can there-










to be one of the strengths of the study, it should also be mentioned that
some drugs sold may still be unused, either in pharmacies or in the
patient’s home. Third, we calculated the DDD figures in relation to the
total population, even though the use of hypnotics is exceptional among
children (about 1 million in Finland). Fourth, physicians recommend
only using antidepressants in small doses to start with33 and only using
full clinical doses after a few weeks. This short transition period overlaps
with the use of the given drug for insomnia treatment. If the total use of
some antidepressant has shown a large increase, it would also have
slightly increased its sale in small sub-clinical doses, making interpreta-
tion difficult. However, we found that the increase in the use of small
sub-clinical doses of amitriptylin accounted for 86.5% of the total
increase in the use of the drug, suggesting that the increase in the use
of small sub-clinical doses is probably not explained by the general
increase in the use of the drug for the treatment of depression. As a lim-
itation of this conclusion it must, however, be admitted that we cannot
exclude the possible effect of improper use of sub-clinical doses of anti-
depressants to treat depression which may have partly increased their
use. However, we feel that it is unlikely that the practice of improper use
of antidepressants would have become more common during the last
decade given the amount of education and information given to health
care professionals about the treatment of depression. In addition, a fur-
ther limitation, regarding inferences on the causes of the increase in use
of sub-clinical doses of amitriptylin, is that it is also used in low doses for
pain relief, such as migraine34 and irritable bowel syndrome.35 However,
the use of quetiapine and pregabalin for pain in low sub-clinical doses is
most uncommon. The emergence of various new alternatives for pain
management suggests that there may not have been much pressure to
increase the use of antidepressants for pain management in Finland. 
Conclusions
The results of this study suggest that the decrease in the annual use
of traditional hypnotics is, for the most part, explained by a shift in the
prescribing practices of physicians. Currently, insomnia is increasing-
ly treated by small sub-clinical doses of antidepressants and some other
new drugs. This means that such drugs are being used for purposes
other than those for which they were originally developed. This practice
should not prevent the treatment of insomnia via behavioral therapy
and other recommended forms of non-pharmacological treatment, and
their more general use in outpatient care. The long-term consequences
of this practice are not known and, therefore, the situation should be
followed-up with further study.
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